Venous Thromboembolism During Pregnancy

LEE T. DRESANG, MD, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
PAT FONTAINE, MD, MS, University of Minnesota, Minneapolis, Minnesota
LARRY LEEMAN, MD, MPH, University of New Mexico School of Medicine, Albuquerque, New Mexico
VALERIE J. KING, MD, MPH, Oregon Health & Science University, Portland, Oregon

Venous thromboembolism is the leading cause of maternal death in the United States. Pregnancy is a risk factor for deep venous thrombosis, and risk is further increased with a personal or family history of thrombosis or thrombophilia. Screening for thrombophilia is not recommended for the general population; however, testing for inherited or acquired thrombophilic conditions is recommended when personal or family history suggests increased risk. Factor V Leiden and prothrombin G20210A mutation are the most common inherited thrombophilias, and antiphospholipid antibody syndrome is the most important acquired defect. Clinical symptoms of deep venous thrombosis may be subtle and difficult to distinguish from gestational edema. Venous compression (Doppler) ultrasonography is the diagnostic test of choice. Pulmonary embolism typically presents postpartum with dyspnea and tachypnea. Multidetector-row (spiral) computed tomography is the test of choice for pulmonary embolism. Warfarin is contraindicated during pregnancy, but is safe to use postpartum and is compatible with breastfeeding. Low-molecular-weight heparin has largely replaced unfractionated heparin for prophylaxis and treatment in pregnancy. (Am Fam Physician. 2008;77(12):1709-1716. Copyright © 2008 American Academy of Family Physicians.)

Venous thromboembolism (VTE), which encompasses deep venous thrombosis (DVT) and pulmonary embolism (PE), complicates 0.5 to 3.0 per 1,000 pregnancies,1 and is the leading cause of maternal mortality in the United States.2 A 2007 American College of Physicians and American Academy of Family Physicians practice guideline,1 based on a systematic review,3 found only 11 high quality studies relating to the management of VTE in pregnancy, and concluded that there is inadequate evidence for definitive recommendations.1

Risk Factors
Virchow’s triad of hypercoagulation, vascular damage, and venous stasis all occur in pregnancy, resulting in a relative risk of 4.3 (95% confidence interval [CI], 3.5 to 5.2) for VTE in pregnant or postpartum women compared with nonpregnant women.4

VTE risk factors include age greater than 35 years, obesity (body mass index higher than 30 kg per m²), grand multiparity, and a personal or family history of VTE or thrombophilia.5,6 Bed rest, immobility for four days or longer, hyperemesis, dehydration, medical problems (e.g., severe infection, congestive heart failure, nephrotic syndrome), preeclampsia, severe varicose veins, surgery, and trauma are also associated with an increased risk.6,7 Cesarean delivery significantly increases VTE risk compared with vaginal delivery (odds ratio [OR] = 13.3; 95% CI, 3.4 to 51.4).8

Thrombophilic Disorders
Approximately 50 percent of pregnant women with VTE have a thrombophilia, compared with 10 percent of the general population.9 Current evidence does not support universal thrombophilia screening.9 However, expert opinion suggests testing women with a personal or strong family history of thrombosis or thrombophilia.10 During pregnancy, results must be interpreted with caution, because protein S levels normally fall in the second trimester.11 Massive thrombus and nephrotic syndrome can decrease antithrombin levels, and liver disease decreases protein C and S levels.12

Thrombophilic disorders may be inherited or acquired.13,14 Factor V Leiden and
prothrombin G20210A mutations are the most common.\textsuperscript{13} Antiphospholipid antibody syndrome, the most important acquired thrombophilia in pregnancy, is defined by the presence of antiphospholipid antibodies and one or more clinical manifestations, most commonly thrombosis or recurrent miscarriage.\textsuperscript{15} A positive test for lupus anticoagulant, or medium-to-high titers of anticardiolipin immunoglobulin G or M antibodies, provides adequate laboratory confirmation of antiphospholipid antibody syndrome if found twice at least six weeks apart.\textsuperscript{15}

Thrombophilies are associated with pregnancy complications, including early and late pregnancy loss, intrauterine growth restriction, and placental abruption.\textsuperscript{9}

**Signs and Symptoms**

**DEEP VENOUS THROMBOSIS**

DVT occurs with equal frequency in each trimester and postpartum.\textsuperscript{16} During pregnancy, 78 to 90 percent of DVTs occur in the left leg\textsuperscript{5,7} and 72 percent in the iliofemoral vein, where they are more likely to embolize.\textsuperscript{5} In nonpregnant patients, 55 percent are in the left leg and 9 percent in the iliofemoral vein.\textsuperscript{5}

Diagnosing DVT is difficult during pregnancy. Clinical suspicion is confirmed in 10 percent of pregnant women, compared with 25 percent of nonpregnant patients.\textsuperscript{17} Typical symptoms are unilateral leg pain and swelling. Pain with foot dorsiflexion (Homan’s sign) is neither sensitive nor specific for diagnosing DVT in patients who are not pregnant;\textsuperscript{18} however, data are lacking for this in patients who are pregnant.

**PULMONARY EMBOLISM**

PE occurs more commonly during the postpartum period than during pregnancy (relative risk = 15.0; 95% CI, 5.1 to 43.9),\textsuperscript{4} and 64 percent of postpartum VTEs occur after cesarean delivery.\textsuperscript{7} Clinical presentation varies from mild dyspnea and tachypnea to dramatic cardiopulmonary collapse. Symptoms of dyspnea are nonspecific in pregnancy. Of clinically suspected PE, only 4 percent are confirmed in pregnant patients, versus 30 percent in nonpregnant patients.\textsuperscript{17}

**Diagnostic Testing**

**DEEP VENOUS THROMBOSIS**

Figure 1 presents an approach to the diagnosis and treatment of DVT in pregnancy derived from studies of nonpregnant patients.\textsuperscript{19,20} In nonpregnant women, a negative (low) D-dimer test combined with a low clinical probability score has a negative predictive value higher than 99.5 percent when a highly sensitive assay (e.g., enzyme-linked immunosorbent assay, latex turbidimetric assay) is used.\textsuperscript{19,20} However, D-dimer values increase progressively throughout pregnancy, and the ranges for normal values by gestational week are not yet universally established.\textsuperscript{21,22} Although a low D-dimer may be helpful in ruling out DVT, a positive (high) D-dimer result will be common during pregnancy and always requires confirmatory testing.\textsuperscript{12,20}

Venous compression ultrasonography is the test of choice for diagnosing DVT because it is noninvasive, safe, and relatively inexpensive.\textsuperscript{12,20} In nonpregnant patients, it is 89 to 96 percent sensitive and 94 to 99 percent specific for symptomatic proximal lower extremity DVT.\textsuperscript{19} Sensitivity is lower in patients who are asymptomatic or have a calf DVT.\textsuperscript{19}

In nonpregnant patients, computed tomography and magnetic resonance imaging have equivalent or better sensitivities and specificities than ultrasonography for DVT detection.\textsuperscript{23} Data are lacking for pregnant patients.
Venography still serves as the definitive test for diagnosing DVT\(^9\) and may be used in clinical situations where noninvasive tests are equivocal, empiric anticoagulation is relatively contraindicated, and clinical suspicion is high.\(^{24}\)

**PULMONARY EMBOLISM**

*Figure 2* outlines a diagnostic approach for suspected PE based on expert opinion derived from studies mostly involving nonpregnant patients.\(^{24-27}\)

With low or moderate clinical suspicion, a negative highly sensitive D-dimer test rules out PE.\(^{25,28}\) If D-dimer testing is positive, or if clinical suspicion is high, additional testing is needed. Some authorities recommend lower extremity venous compression ultrasonography as the next test because if DVT is present, anticoagulant treatment will be the same as for PE, and venous compression ultrasonography avoids fetal radiation exposure.\(^{12,28}\)

When D-dimer testing and venous compression ultrasonography are inconclusive, multidetector-row (spiral) computed tomography has become the test of choice for diagnosing PE in pregnancy.\(^{12,24,26}\) Single-slice computed tomography is inadequate in diagnosing peripheral PE, but newer-generation spiral computed tomography, tested in nonpregnant patients, has shown positive and negative predictive values comparable with pulmonary angiography.\(^{27}\) Fetal exposure to radiation is lower with spiral computed tomography than with ventilation-perfusion (V/Q) scanning (less than 130 µGy and 370 µGy, respectively), and fetal exposure to spiral computed tomography nonionic contrast appears safe.\(^{29}\) Spiral computed tomography does expose the maternal breast to greater radiation, and V/Q scanning may be preferred in women with a family history of breast cancer.\(^{12}\) A cost-benefit analysis supports spiral computed tomography as the preferred test for diagnosing PE during pregnancy.\(^{30}\)

V/Q scanning may be used if spiral computed tomography is unavailable. Based on data from nonpregnant patients, PE can be excluded with a normal or low probability V/Q scan if clinical suspicion is low to moderate.\(^{25}\) Likewise, PE can be diagnosed with a high probability scan if clinical suspicion is moderate to high.\(^{25}\) In a study of V/Q scanning in 120 pregnant women with suspected
PE, 73.5 percent were normal and 1.8 percent were high probability, compared with 27 to 36 percent normal and 8 to 14 percent high probability scans in nonpregnant patients. When V/Q scanning is nondiagnostic, additional options include repeat leg compression ultrasonography, repeat V/Q scanning, spiral computed tomography, magnetic resonance imaging, and pulmonary angiography. Arterial blood gas monitoring (with the patient sitting upright for greatest accuracy), chest radiography, and electrocardiography (looking for right ventricular hypertrophy) can be done in unstable and immobile patients and may help diagnose PE or suggest other conditions.

**Treatment**

The optimal treatment of VTE during pregnancy has not been studied via randomized controlled trials, and clinical recommendations are based on expert opinion. Stabilization is the first priority. Airway, breathing, and circulation should be addressed immediately and may require management in the intensive care unit. With life-threatening PE, thrombolytic therapy, percutaneous catheter thrombus fragmentation, or surgical embolec- tomy may be used, depending on local resources. Good evidence about the effectiveness and safety of thrombolytic therapy is lacking. Empiric anticoagulation may be started if clinical suspicion is high, then discontinued if VTE is excluded.

**ANTICOAGULATION IN PREGNANCY**

Therapeutic anticoagulation is indicated when DVT or PE is diagnosed. Anticoagulation options include low-molecular-weight heparins (LMWHs), unfractionated heparin (UFH), and warfarin (Coumadin; postpartum only).

LMWHs are replacing UFH as the first-choice medications for VTE treatment and prophylaxis in pregnancy. In nonpregnant women, randomized trials have shown LMWHs to have equivalent or better effectiveness compared with UFH. In pregnancy, a systematic review concluded that LMWH is safe and effective and that there is no evidence to favor one LMWH over another. Excretion in breast milk is minimal. Compared with UFH, LMWHs have lower rates of adverse effects, including heparin-induced thrombocytopenia, symptomatic osteoporosis, bleeding, and allergic reactions.

Warfarin should be avoided during pregnancy. It crosses the placenta and increases the risk of miscarriage, stillbirth, embryopathy (nasal hypoplasia or stippled epiphyses), central nervous system abnormalities, and maternal and fetal hemorrhage. Warfarin is compatible with breastfeeding.

Data derived from nonpregnant populations suggest that therapeutic anticoagulation following a first episode of VTE should continue for at least six months from diagnosis. Current recommendations for the duration of treatment in pregnancy range from three
Table 1. Therapeutic Dosing of Heparin in Pregnancy

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage*</th>
</tr>
</thead>
<tbody>
<tr>
<td>LMWH (enoxaparin [Lovenox])</td>
<td>1 mg per kg subcutaneously every 12 hours&lt;sup&gt;12&lt;/sup&gt;</td>
</tr>
<tr>
<td>UFH</td>
<td>IV loading dose of 5,000 IU followed by</td>
</tr>
<tr>
<td></td>
<td>Continuous IV infusion for a total of</td>
</tr>
<tr>
<td></td>
<td>at least 30,000 IU over 24 hours&lt;sup&gt;10&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>or 10,000 IU subcutaneously every 8 hours&lt;sup&gt;41&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>or 20,000 IU subcutaneously every 12 hours&lt;sup&gt;41&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Monitor aPPT and adjust dose to maintain</td>
</tr>
<tr>
<td></td>
<td>aPPT 1.5 to 2 times control value&lt;sup&gt;32&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*aPPT = activated partial thromboplastin time; IV = intravenous; IU = International Units; LMWH = low-molecular-weight heparin; UFH = unfractionated heparin.

<sup>*—Subcutaneous LMWH or adjusted-dose subcutaneous UFH can be used for initial and long-term treatment. IV UFH is followed by subcutaneous LMWH or adjusted-dose subcutaneous UFH.<sup>31</sup></sup>

Information from references 10, 12, 32, and 41.

Evidence is insufficient to recommend for or against an inferior vena cava filter if anticoagulation is contraindicated or repeat PE occurs despite adequate anticoagulation.<sup>3</sup>

**Prophylaxis**

Systematic reviews of observational studies have found VTE prophylaxis with LMWH to be safe and effective in pregnancy, but there are no randomized controlled trials confirming this.<sup>35,42</sup> Table 2 lists representative doses for LMWH prophylaxis during pregnancy.<sup>6</sup>

Table 2. Prophylactic Dosing of Heparin in Pregnancy

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enoxaparin (Lovenox)&lt;sup&gt;6&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>110 to 199 lb (50 to 90 kg)</td>
<td>40 mg SC daily</td>
</tr>
<tr>
<td>&lt; 110 lb</td>
<td>20 mg SC daily</td>
</tr>
<tr>
<td>&gt; 199 lb</td>
<td>40 mg SC every 12 hours</td>
</tr>
<tr>
<td>UFH&lt;sup&gt;33&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>First trimester</td>
<td>5,000 IU SC twice daily</td>
</tr>
<tr>
<td>Second trimester</td>
<td>7,500 IU SC twice daily</td>
</tr>
<tr>
<td>Third trimester</td>
<td>10,000 IU SC twice daily</td>
</tr>
</tbody>
</table>

IU = International Units; SC = subcutaneously; UFH = unfractionated heparin.

Information from references 6 and 43.
Table 3. Clinical Indications for Anticoagulant Prophylaxis

<table>
<thead>
<tr>
<th>Personal history of DVT or PE, no known thrombophilia</th>
<th>DVT or PE with thrombogenic event (e.g., hip fracture, prolonged surgery)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start: This indication is controversial; patient and caregivers may decide whether to use antenatal heparin prophylaxis; regardless of this decision, postpartum prophylaxis is recommended</td>
<td></td>
</tr>
<tr>
<td>Stop: Six weeks postpartum</td>
<td></td>
</tr>
<tr>
<td>DVT or PE with no thrombogenic event</td>
<td></td>
</tr>
<tr>
<td>Start: As early in pregnancy as possible</td>
<td></td>
</tr>
<tr>
<td>Stop: Six weeks postpartum; those with recurrent or life-threatening events may require long-term prophylaxis</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Personal history of DVT or PE, known thrombophilia</th>
<th>DVT or PE with thrombogenic event (e.g., hip fracture, prolonged surgery)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Start: As early in pregnancy as possible</td>
<td></td>
</tr>
<tr>
<td>Stop: Six weeks postpartum; 12 months or longer of anticoagulation is indicated for nonpregnant patients with a first episode of VTE (DVT or PE) and antiphospholipid syndrome or combined factor V Leiden and prothrombin G20210A mutations; six to 12 months of anticoagulation is indicated for nonpregnant patients with a first episode of VTE and antithrombin, protein C or S deficiencies, heterozygous factor V Leiden or prothrombin G20210A mutations, homocystinemia or factor VIII levels &gt; 90 percent of normal; lower-quality evidence suggests long-term anticoagulation for nonpregnant patients with a first episode of VTE and any of the above thrombophilias; women with any thrombophilia and recurrent or life-threatening events may require long-term prophylaxis</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No history of DVT or PE, known thrombophilia</th>
<th>DVT or PE with thrombogenic event (e.g., hip fracture, prolonged surgery)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antithrombin deficiency, homozygous factor V Leiden; two or more minor risk factors (i.e., heterozygous factor V Leiden and heterozygous prothrombin G20210A mutations)</td>
<td></td>
</tr>
<tr>
<td>Start: As early in pregnancy as possible</td>
<td></td>
</tr>
<tr>
<td>Stop: Six weeks postpartum</td>
<td></td>
</tr>
<tr>
<td>Antiphospholipid antibodies</td>
<td></td>
</tr>
<tr>
<td>Start: Low-dose aspirin with or without heparin as early in pregnancy as possible</td>
<td></td>
</tr>
<tr>
<td>Stop: Six to eight weeks postpartum</td>
<td></td>
</tr>
<tr>
<td>Protein C or S deficiency</td>
<td></td>
</tr>
<tr>
<td>Start: As early in pregnancy as possible; peripartum and postpartum may be sufficient if no family history of thrombophilia, no severe protein C deficiency (less than 50 percent of normal levels), and no additional risk factor, such as immobilization, hospitalization, surgery, infection or thrombophlebitis</td>
<td></td>
</tr>
<tr>
<td>Stop: Six weeks postpartum</td>
<td></td>
</tr>
<tr>
<td>Single heterozygous factor V Leiden or heterozygous prothrombin G20210A mutation</td>
<td></td>
</tr>
<tr>
<td>Start: No prophylaxis indicated unless family history of venous thromboembolism and additional risk factor such as immobilization, hospitalization, surgery, infection, or thrombophlebitis; prophylaxis started peripartum or postpartum when indicated</td>
<td></td>
</tr>
<tr>
<td>Stop: Four to six weeks postpartum</td>
<td></td>
</tr>
</tbody>
</table>

DVT = deep venous thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism.

Information from references 5, 10, 15, 32, 39, and 40.

Venous Thromboembolism

prophylactic doses of LMWH and subcutaneous UFH. Table 3 summarizes recommendations for the type and duration of prophylaxis based on specific clinical risk factors. Consultation should be considered for high-risk thrombophilias such as antithrombin deficiency.

Low-dose aspirin (75 to 81 mg) is sometimes used for women with an increased risk of thrombosis that does not meet the threshold for prophylactic heparin (e.g., a woman with a mild thrombophilia and no history of VTE). Due to the lack of studies of aspirin for this indication, such treatment is of unknown benefit; however, low-dose aspirin is safe to use during pregnancy.

Postpartum thromboprophylaxis is not routinely indicated following vaginal delivery, but may become necessary because of labor-related risk factors, such as prolonged labor, mid-forceps delivery, and immobility after delivery.

Unless other VTE risk factors are also present, women who undergo a scheduled cesarean delivery are not routinely placed on pharmacologic VTE prophylaxis. However, mechanical prophylaxis with pneumatic compression stockings has been shown to provide effective post-cesarean thromboprophylaxis. Graduated compression stockings provide effective prophylaxis in nonpregnant postoperative patients.

A decision analysis comparing pneumatic compression stockings with no intervention for post-cesarean VTE prophylaxis found the former to be cost-effective.

This article is one in a series on "Advanced Life Support in Obstetrics (ALSO)," initially established by Mark Deutchman, MD, Denver, Colo. The series is now coordinated by Patricia Fontaine, MD, MS, ALSO Managing Editor, Minneapolis, Minn., and Larry Leeman, MD, MPH, ALSO Associate Editor, Albuquerque, N.M.

The Authors

LEE T. DRESANG, MD, is an associate professor and departmental maternity care clinical coordinator in the Department of Family Medicine at the University of Wisconsin School of Medicine and Public Health, Madison. He is a graduate of Indiana University School of Medicine, Indianapolis, and completed a family practice residency at the University of New Mexico, Albuquerque, and the Tacoma Family Medicine Rural Health Fellowship in Tacoma, Washington. Dr. Dresang is a member of the Advanced Life Support in Obstetrics (ALSO) Advisory Board.
PAT FONTAINE, MD, MS, is an associate professor of family medicine and community health at the University of Minnesota, Minneapolis. She is a graduate of the University of Michigan Medical School, Ann Arbor, and completed a family medicine residency at the North Memorial Program of the University of Minnesota Affiliated Family Medicine Residencies.

LARRY LEEMAN, MD, MPH, is an associate professor of family and community medicine, and obstetrics and gynecology, at the University of New Mexico School of Medicine, Albuquerque. He is a medical director of the mother-baby unit at the University of New Mexico Hospital, Albuquerque. Dr. Leeman is a graduate of the University of California, San Francisco, School of Medicine. He completed a family medicine residency at the University of New Mexico School of Medicine and a fellowship in obstetrics at the University of Rochester (N.Y.) School of Medicine.

VALERIE J. KING, MD, MPH, is an associate professor in the Department of Family Medicine at Oregon Health & Science University, Portland. She is an ALSO Advisory Faculty member. She completed medical school, residencies in family and preventive medicine, and research fellowships at the University of North Carolina at Chapel Hill.

Address correspondence to Lee D. Dresang, MD, MS, 10 Dane St., Madison, WI 53713 (e-mail: Lee.Dresang@fammed.wisc.edu).

REFERENCES


Venous Thromboembolism